UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The Effect of Exacerbation History on Outcomes in the IMPACT Trial

Halpin, DMG; Dransfield, MT; Han, MK; Jones, CE; Kilbride, S; Lange, P; Lipson, DA; ... Criner, GJ; + view all (2020) The Effect of Exacerbation History on Outcomes in the IMPACT Trial. European Respiratory Journal , 55 , Article 1901921. 10.1183/13993003.01921-2019. Green open access

[thumbnail of Accepted Manuscript]
Preview
Text (Accepted Manuscript)
Lomas_The Effect of Exacerbation History on Outcomes in the IMPACT Trial_AAM2.pdf - Accepted version

Download (3MB) | Preview
[thumbnail of Supplementary Material]
Preview
Text (Supplementary Material)
Lomas_The Effect of Exacerbation History on Outcomes in the IMPACT Trial_SuppM.pdf - Accepted version

Download (319kB) | Preview

Abstract

IMPACT, a 52-week, randomised, double-blind trial, assessed the efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI or UMEC/VI in patients with symptomatic chronic obstructive pulmonary disease and a history of exacerbations.Subgroup analyses assessed whether the efficacy of FF/UMEC/VI versus FF/VI or UMEC/VI, and UMEC/VI versus FF/VI, varies according to prior exacerbation history, and the combined effects of exacerbation history and blood eosinophil counts. Three subgroups were defined: single moderate (1 moderate/no severe; n=3056 [30%]), frequent moderate (≥2 moderate/no severe; n=4628 [45%]) and severe (≥1 severe/any moderate; n=2671 [26%]). Endpoints included annual on-treatment moderate/severe exacerbation rate (pre-specified), lung function, and health status (both post hoc).Moderate/severe exacerbation rates were reduced in the FF/UMEC/VI group versus FF/VI (% reduction [95% confidence interval]: single moderate: 20% [10-29]; frequent moderate: 11% [2-19]; severe: 17% [7-26]) and versus UMEC/VI (single moderate: 18% [5-29]; frequent moderate: 29% [21-37]; severe: 26% [14-35]). Moderate/severe exacerbation rates were reduced in the FF/VI group versus UMEC/VI in the frequent moderate subgroup; a numerical reduction was observed in the severe subgroup (single moderate: 2% [-12-18]; frequent moderate: 21% [11-29]; severe: 11% [-3-22]). Moderate/severe exacerbation rates were lower in the FF/VI group compared with UMEC/VI in patients with higher eosinophil counts. FF/UMEC/VI improved lung function and health status versus both dual therapies irrespective of exacerbation subgroup. UMEC/VI improved lung function versus FF/VI in all subgroups.Triple therapy was more effective than dual regardless of exacerbation history, consistent with results in the intent-to-treat population. Comparisons between dual therapies were influenced by prior exacerbation history and eosinophil counts.Funding: GSK (CTT116855/NCT02164513).

Type: Article
Title: The Effect of Exacerbation History on Outcomes in the IMPACT Trial
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1183/13993003.01921-2019
Publisher version: https://doi.org/10.1183/13993003.01921-2019
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: COPD, exacerbation history, exacerbation rates, triple therapy, ICS/LABA, LAMA/LABA, eosinophil count
UCL classification: UCL
UCL > Provost and Vice Provost Offices > VP: Health
URI: https://discovery.ucl.ac.uk/id/eprint/10095453
Downloads since deposit
20Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item